The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of first-line comprehensive genomic profiling on survival outcomes for patients with advanced solid tumors who received molecularly-matched therapies: 3-year follow-up of the prospective FIRST-Dx study.
 
Sadakatsu Ikeda
Leadership - AIM Precision Therapeutics, Inc.
Stock and Other Ownership Interests - AIM Precision Therapeutics, Inc.
Honoraria - ACT Genomics; ACT Med; AstraZeneca; Bristol-Myers Squibb-Ono Pharmaceutical; Canon Medical System; Chugai Pharma; Guardant Health; MSD; Novartis; Roche; Taiho Pharmaceutical
Consulting or Advisory Role - BostonGene; Illumina
Research Funding - Canon Medical System (Inst); Flatiron Health (Inst)
Travel, Accommodations, Expenses - Guardant Health
 
Junichi Matsubara
No Relationships to Disclose
 
Kumi Mukai
No Relationships to Disclose
 
Masahiro Yoshioka
No Relationships to Disclose
 
Hidenori Kage
Honoraria - Amgen; AstraZeneca; Bayer Yakuhin; Boehringer Ingelheim Seiyaku; Bristol-Myers Squibb Japan; Chugai Pharma; Chugai Pharma; Eiken Chemical; GenMine Labs; Kyorin; Merck; Merck; MSD; Ono Yakuhin; Pfizer; Taiho Pharmaceutical; Takeda
 
Katsutoshi Oda
Honoraria - AstraZeneca/Merck; Chugai Pharma; Konica Minolta
Research Funding - AstraZeneca/Merck; Konica Minolta
 
Hiromichi Ebi
Honoraria - Amgen; Amoy Diagnostics; AstraZeneca; Boehringer Ingelheim Seiyaku; Chugai Pharma; Guardant Health AMEA; Incyte Japan; Konica Minolta; Merck Serono; Ono Pharmaceutical; Otsuka; Riken Genetics
Consulting or Advisory Role - Amgen; Amoy Diagnostics; Astellas Pharma
Research Funding - Amoy Diagnostics; Astellas Pharma; Loxo/Lilly (Inst)
 
Kei Muro
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Lilly; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Chugai Pharma; Ono Pharmaceutical
Research Funding - Amgen (Inst); Chugai Pharma (Inst); MSD (Inst); PRA Health Sciences (Inst); Taiho Pharmaceutical (Inst)
 
Shinya Kajiura
No Relationships to Disclose
 
Ryuji Hayashi
Honoraria - AstraZeneca; Chugai Pharma; Lilly Japan; MSD K.K; Roche; Shionogi
 
Reiko Ashida
No Relationships to Disclose
 
Masayuki Kitano
No Relationships to Disclose
 
Manabu Muto
Speakers' Bureau - Chugai Pharma; Daiichi Sankyo/Lilly; Meiji Seika Kaisha; Merck; MSD; Novartis; Olympus; Ono Pharmaceutical; Phaizar; Shionogi
Research Funding - Ark MS; AstraZeneca; Canon Medical System; Chugai Pharma; Fujitsu Japan (Inst); H.U. Group Holdings; Meiji Seika Kaisha; NTT; NTT Data; Taiho Pharmaceutical; Takeda